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BACKGROUND/PURPOSE: Leishmaniasis is currently a threat in 80 countries around the world, and 
cutaneous Leishmaniasis accounts for more than 5% of new cases. It is a problematic disease in Iran, and 
preparing a protective vaccine has been a major goal of medical investigations. The objective of this study 
was to compare the protective effects of a cocktail vaccine candidate encoding various Leishmania major 
antigens in highly susceptible (Balb/C, or type I mice) and resistant (laboratory small white, or type II) 
mice.
METHODS: A new antigen formulation was evaluated in type I and II mice. Leishmania major promas-
tigotes was cultured and harvested at different growth stages, and a cocktail made from the harvested or-
ganisms. The preparations were tested for sterility and contamination by endotoxin. Five different 
methods were utilized to produce a crude antigen preparation. The protein levels of the antigen prepara-
tions were measured using the Lowry method, and the antigens were intradermally injected using differ-
ent protocols for type I and II mice. After 38 days, all mice were euthanized with diethyl ether, and spleens 
were removed. Histological sections were prepared, stained with hematoxylin and eosin and changes to 
the splenic white pulp (SWP) were studied microscopically.
RESULTS: Compared with the control groups, there was a drastic change in white pulp structure. The 
size increases of the SWP were dependent on the injection group and mouse strain. There was a remarka-
ble expansion of lymphoid follicles in the treated groups in both mice strains.
CONCLUSION: The new antigen formulation was able to stimulate and expand the lymphoid constitu-
ents of spleen tissue. The SWP is where immune responses and antibodies are produced. Therefore, the 
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Introduction
Leishmaniasis is one of the major illnesses in tropical and 
subtropical areas, including countries of South and 
Central America, Africa and Asia. The disease is endemic 
in Iran and appears as both cutaneous and visceral forms. 
To prevent cutaneous Leishmaniasis, different antigen 
preparations have been used as vaccines. Merthiolated 
killed antigens from five different strains of Leishmania 
had been used as vaccines.1–3 The vaccine comprised a mix-
ture of equal amounts of freeze-thawed intact parasites,4,5 
and irradiated and heated antigen2,5 injected intrader-
mally. An alternative strategy using attenuated organisms 
allows the development of an immune response similar 
to that of the natural infection, with exposure to a much 
larger range of antigens than can be achieved by using 
more refined subunit vaccines.6
A live Leishmania vaccine was prepared in Venezuela 
to vaccinate subjects against Leishmania mexicana and 
Leishmania braziliensis.6 Evidence for a role for interleukin 
(IL)-10 comes from studies demonstrating increased 
IL-10 mRNA expression in bone marrow, lymph nodes, 
and spleen. Nearly 1.2 million people in Iran between 
1982–1986 received such a live vaccine.7 Approximately 
50% of those who received this vaccine developed skin le-
sions and of those, 93% demonstrated a positive leish-
manin-delayed hypersensitivity skin test, a good field 
marker of population immunity.6 To potentate the effec-
tiveness of the vaccine, Bacillus Calmette-Guérin (BCG) 
was also used. There have been attempts to prepare a pro-
tective and safe vaccine by several Iranian groups; how-
ever, it seems that more research are required to evaluate 
different preparations of Leishmania antigen for vaccina-
tion purposes. Clinically, the killed vaccine has not been 
successful.8 However, little success has been made in the 
treatment of human, or experimental murine, Leishmaniasis 
using naturally virulent organisms, irradiated organisms, or 
genetically manipulated organisms. Similarly, killed vac-
cines have shown limited immunogenicity and efficacy, 
even when combined with adjuvant (either BCG or alum). 
Interestingly, BCG alone led to a positive leishmanin skin 
test in some individuals, presumably due to antigenic 
cross-reactivity between Mycobacteria and Leishmania.6
Recent evidence has also shown that Leishmania-
human immunodeficiency virus co-infections are a major 
health problem in affected areas.7 The disease is usually 
self-limiting, but the time to lesion resolution varies 
between species and between individuals. The pathology 
of Leishmania infection is determined not only by the 
parasite species, but also by host genetics and immune 
factors. Most of the experimental immunological data 
comes from mouse models, and less is known about the 
immunology of human Leishmaniasis. Although mouse 
models have been used for the study of both cutaneous 
and visceral Leishmaniasis, they more closely reflect the 
situation in human cutaneous Leishmaniasis than vis-
ceral disease. Leishmaniasis in general, particularly cuta-
neous Leishmaniasis, is probably one of a few parasitic 
diseases that is most likely to be controlled by vaccines.
During the past several decades, extensive efforts have 
been made to search for an effective Leishmania vaccine. 
Vaccine formulations incorporating killed, live attenuated 
parasites, recombinant Leishmania proteins, or DNA en-
coding Leishmania proteins, as well as immunomodula-
tors from sandfly saliva have been examined. A typical 
inoculum contains around 100–1,000 metacyclic promas-
tigotes, which quickly become engulfed by leucocytes, 
particularly macrophages, neutrophils, and dendritic cells.6
Although there is no vaccine against Leishmania to 
date, several of the vaccine preparations are at advanced 
stages of clinical testing. In the present report, the kinet-
ics of the splenic white pulp (SWP) expansion in two types 
of mice were studied to compare the effects of the differ-
ent Leishmania cocktail vaccines, and injection doses 
effect of the antigen preparations on secondary immune responses, adaptive immunity, and antibody 
production is important in determining the susceptibility of mice to cutaneous Leishmaniasis and the 
induction of immunity.
KEYWORDS: antigen, cutaneous Leishmaniasis
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(100–500 μg/mL of protein) with placebo groups. The aim 
of this study was to compare the protective effects of a 
candidate cocktail vaccine encoding various Leishmania 
major antigens in highly susceptible (Balb/C or type I) 
and resistant (laboratory small white, or type II) mice.
Methods
This study was done in compliance with the Helsinki 
Declaration, and the protocol was approved by research 
deputy of Tehran University of Medical Sciences, Tehran, 
Iran.
Animal model
For detail procedure please refer to Latifynia and Mohaghegh 
Hazrati, 2008.9 In brief, Balb/C and traditional white lab-
oratory mice (n = 192) were obtained at three months old 
from the Razi institute.
Culture and isolation of Leishmania parasites
Leishmania parasites and promastigote antigens from the 
L. major WHO strain were kindly provided by the Pasteur 
Institute, and grown in NNN (Novy-MacNeal-Nicoll) me-
dium supplemented with Hemin, Homa, RPMI 1640, nor-
mal saline, and/or 5–10% heat inactivated fetal calf serum.
Harvested parasites were washed three times with ei-
ther 0.9% normal saline or phosphate buffered saline. The 
parasites were counted using a Neubar chamber and then 
kept at –80ºC until use. Accumulative parasites were then 
diluted to a concentration of 330 × 106/mL and separated 
to five equal batches. The first batch was killed by pas-
teurization in water at 56ºC for 30 minutes. The second 
batch was autoclaved at 121ºC for 30 minutes. The third 
batch was merthiolated for 30 minutes at a dilution of 
1:10,000. The fourth batch was freeze-thawed three times 
and the fifth batch was left innate.
Vaccine preparation
The five batches were mixed and centrifuged, and the sedi-
ments were dispensed into sterile vials. The Leishmania 
component of the vaccines was tested for complete para-
site killing by cultivation on blood agar plates, and by in-
jection into the footpads of type I and II mice. Sterility and 
routine tests for toxicity were described previously.9 These 
tests were carried out at the Institute of Pasteur, which 
also verified the sterility of the preparations and certified 
each lot of vaccine as containing dosages of 1,000–5,000 μg/
mL protein. The sugar contentment was determined by the 
phenol/sulfuric acid method.10 Endotoxin measurements 
were performed to determine any possible contamination 
of the antigen preparations with endotoxin method.11 The 
vaccine was stored at 4ºC until use.
Vaccine injection
Detailed procedures were descibled previously.9 In brief, 
just before injection, the BCG vaccine “SSI” was sus-
pended in Sauton SSI diluent and 0.1 mg of BCG (first 
dose) or 0.01 mg of BCG (successive dose) was added to 
each vial containing promastigotes. All doses were injected 
intradermally into the tails (or foot pads) of type II mice.
Three injection groups [(1) Leishmania antigen plus 
booster dose of Leishmania antigen; (2) Leishmania anti-
gen plus BCG; and (3) Leishmania antigen plus BCG plus 
booster dose of Leishmania antigen], and five injection 
dosages (100, 200, 300, 400, or 500 μg protein) were used. 
Each dosage group contained five mice. Five mice received 
no injection, and five mice were injected with sterile saline 
alone. Among the mice were genetically susceptible and 
resistant mice.
The protective response was evaluated by analysis of 
secondary immune system responses against Leishmanial 
antigens 38 days after antigen injection. The mice were 
euthanized, and their spleens removed. The spleens were 
preserved in 10% formalin solution, and pathologic sections 
were prepared.
Hematocylin and eosin staining
Fixed spleens in paraffin blocks were processed and sec-
tioned in a tissue processor. Tissue sections (5–6 μm thick) 
were prepared and stained with Hematoxylin and Eosin. 
SWP section diameters were measured and compared with 
each other, and with the controls.
Statistical analysis
Data were analyzed using SPSS (SPSS Inc., Chicago, IL, 
USA). Means were compared by standard analysis of 
variance/simple factorial tests, and by one-, two- and 
three-way Student–Newman–Keuls methods. Correlation 
coefficient analysis was determined using a Pearson bivar-
iate, two tailed test.
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Results
To evaluate of the kinetics of the SWP expansion in the 
two types of mice, and to compare the efficiency of 
the cocktail vaccine candidates, we first identified the 
optimal size of the SWP after inoculation of the cocktail 
vaccine, and compared the results with those obtained 
after injections of saline, the BCG placebo, and no injec-
tion at all.
Analysis of variance results were based on the amount 
of SWP increase in the different injection groups/mouse 
types. The effects of the dosage of the cocktail vaccine 
(100–500 μg) were compared within, and between all groups 
(1, 2, and 3).
The peak increase in SWP size was seen after injection 
of 300, 400 and 500 μg vaccine (Figure 1). In contrast, 
lower injection doses (100–200 μg) resulted in little or no 
increase above that seen in normal controls (p < 0.005). 
A confidence interval (CI) of more than 0.95 was consid-
ered significant. The SWP of the mice in all the test groups 
(1, 2, and 3) showed an increase in size, and was notably dif-
ferent from the controls. This difference was independent 
of the injection group and dose. The smallest expansion 
was seen in group 1 (antigen + booster), and the largest in 
group 3 (antigen + BCG + booster), with a 100% difference 
between these two groups.
The minimum size increases were seen in type II mice, 
the maximum in type I (p < 0.001; CI > 0.99%). A vaccine 
dose of 400 μg was associated with the largest increases, and 
200 μg with the smallest (p < 0.001; CI > 0.99%).
Measurements showed that the lowest white pulp size 
was seen in type II mice in group 1 (100 μg antigen). The 
same result was found type I mice in group 1 (200 μg anti-
gen; Table 1). However, when the mouse type was not con-
sidered, the lowest overall increase in white pulp size was 
seen in group 1 (200 μg antigen). When both the group 
and mouse type were not considered, the largest white 
pulp sizes were seen in animals injected with either 400 or 
500 μg of antigen. The analysis of variance results show a 
significant difference in white pulp size between two 
mouse types (p < 0.005; Table 2).
The relationship between the mouse type and injec-
tion group, and vice versa, was significant (p < 0.001; 
CI > 99%) and all groups showed significant differences 
between type I and type II mice (Table 2). When consider-
ing the mouse type against the different injection groups, 
the injected dose of antigen against mouse types, and the 
different injection groups against the injected dose of an-
tigen, significant differences were seen. The increase in 
SWP size was notably different within each group, irre-
spective of injection group and dose.
Discussion
Leishmaniasis is a parasitic infection caused by an obli-
gate, intracellular protozoan of the genus Leishmania (family 
Trypanosomatidae).6 Localized, cutaneous Leishmaniasis 
is characterized by one or more ulcers with limited self-
healing. Patients develop antigen-specific cell mediated 
immunity to the microorganism. The parasite has a di-
genetic life cycle, with an extracellular developmental 
stage in the insect vector (a female phlebotomine sandfly), 
and a developmental stage in mammals, which is mostly 
intracellular.6
An ideal anti-leishmanial vaccine would need to possess 
several attributes; however, not all of them are easily achiev-
able. These include (1) safety; (2) affordability to the popula-
tions in need; (3) induction of CD4+ and CD8+ T cell 
responses, and long-term immunological memory that 
can be boosted by natural infections thus minimizing 
the number of immunizations required; (4) effectiveness 
against species causing cutaneous leishmaniasis and vis-
ceral leishmaniasis; (5) stability at room temperature, elim-
inating the need for a cold chain to preserve potency; and 
(6) effectiveness as a prophylactic as well as a therapeutic 
Figure 1. Sectional spleen pathology showed white pulp size 
expansion 38 days after Leishmania antigen intradermal injec-
tion plus a booster dose after 14 days.
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Table 2. Test of between-subjects effects dependent variable white pulp size distribution
Source Type III Sum of Squares df Mean square F p
M. TYPE 674.38 1 674.38 9.81 0.002
IN. G 167.33 2 83.66 1.22 0.300
DOSE 957.87 4 239.47 3.49 0.010
M.TYPE*IN.G 993.45 2 496.72 7.23 0.001
M.TYPE*DOSE 2,661.41 4 665.35 9.68 0.000
IN.G *DOSE 4,578.82 8 572.35 8.33 0.000
M.TYPE*IN.G*DOSE 3,523.77 8 440.47 6.41 0.000
Error 8,384.11 122 68.72  
Total 167,737.40 154   
Table 1. Distribution of splenic white pulp size on the basis of mouse type, injection group, and received dosea
Group 
Dose Balb/C White laboratory Total
 (μg) n SWP (μm) n SWP (μm) n SWP (μm)
Leishmania antigen only 0 15 11.00 ± 0.00 15 11.90 ± 0.00  30 11.45 ± 0.46
Leishmania antigen +  100  3 10.83 ± 0.29  2 41.50 ± 0.00  5 23.10 ± 16.80
booster 200  4 26.63 ± 4.39  3 20.8 ± 4.62  7 24.14 ± 5.13
 300  2 59.75 ± 3.18  4 28.75 ± 4.27  6 39.08 ± 16.41
 400  5 31.80 ± 9.52  2 42.00 ± 3.54  7 34.71 ± 9.34
 500  8 41.63 ± 11.96  9 34.72 ± 3.41  17 37.97 ± 9.00
 Subtotal 22 34.11 ± 15.54 20 32.85 ± 7.44  42 33.51 ± 12.24
Leishmania antigen + BCG 100  4 34.50 ± 8.29  3 36.00 ± 12.97  7 35.14 ± 9.54
 200  5 23.70 ± 3.96  7 27.71 ± 13.88  12 26.04 ± 10.73
 300  4 18.00 ± 3.11  3 41.50 ± 0.87  7 28.07 ± 12.76
 400  4 49.75 ± 9.49  4 45.63 ± 7.33  8 47.69 ± 8.15
 500  3 34.17 ± 12.66  5 21.60 ± 11.41  8 26.31 ± 12.75
 Subtotal 20 31.50 ± 13.20 22 32.59 ± 13.63  42 32.07 ± 13.27
Leishmania antigen +  100  5 15.50 ± 0.00  3 52.83 ± 20.82  8 29.50 ± 22.30
booster + BCG 200  5 42.00 ± 15.57  4 45.50 ± 4.08  9 43.56 ± 11.44
 300  2 19.00 ± 3.54  3 39.00 ± 2.60  5 31.00 ± 11.25
 400  5 28.80 ± 4.38  4 37.50 ± 5.77  9 32.67 ± 6.57
 500  4 41.13 ± 7.39  5 39.70 ± 18.92  9 40.33 ± 14.14
 Subtotal 21 30.19 ± 13.67 19 42.42 ± 12.90  40 36.00 ± 14.52
Total 0 15 11.00 ± 0.00 15 11.90 ± 0.00  30 11.45 ± 0.46
 100 12 20.67 ± 11.26  8 43.69 ± 15.31  20 29.88 ± 17.14
 200 14 31.07 ± 12.52 14 31.32 ± 13.79  28 31.20 ± 12.93
 300  8 28.69 ± 19.37 10 35.65 ± 6.64  18 32.56 ± 13.80
 400 14 35.86 ± 11.81 10 41.65 ± 6.72  24 38.27 ± 10.25
 500 15 40.00 ± 10.74 19 32.58 ± 12.79  34 35.85 ± 12.33
 Subtotal 78 27.94 ± 15.13 76 31.03 ± 14.61 154 29.47 ± 14.91
aData presented as mean ± standard deviation. SWP = spleen white pulp.
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vaccine. An alternative strategy, using attenuated organ-
isms, allows the development of an immune response clos-
est to that of natural infection, with exposure to a much 
larger range of antigens than is achieved by using more re-
fined subunit vaccines. However, despite pursuing such a 
strategy for human, or experimental murine Leishmaniasis 
using naturally a virulent organisms, or irradiated or geneti-
cally manipulated organisms, there has been little success. 
Similarly, killed vaccines have shown limited immunogenic-
ity and efficacy, even when combined with adjuvant (either 
BCG or alum). Interestingly, BCG alone led to a positive 
leishmanin skin test in some individuals, presumably due to 
antigenic cross-reactivity between Mycobacteria and 
Leishmania. Leishmania parasites possess a variety of vir-
ulence mechanisms that enable the amastigote stage to 
survive in the hostile environment of the phagolysosome.6
A different type of problem has been the loss of viru-
lence after repeated in vitro passage of the parasites, which 
makes the standardization of the vaccine difficult. Efforts 
are being made to improve safety of Leishmanization by 
the inclusion of drug-sensitive Leishmania mutants con-
taining suicide genes for controlled infection,12,13 the in-
clusion of killed parasites to reduce the size and duration 
of lesions, or by using adjuvant that promote more rapid 
onset of anti-Leishmanial immunity and swift healing 
of lesions.14,15 Killed parasite vaccines have been proposed 
as both prophylactic and therapeutic vaccines. The need 
for vaccine(s) against cutaneous Leishmaniasis, and the 
population at risk for whom such vaccines should be 
developed, are briefly discussed.
The current human vaccines are reviewed, as are some 
experimental mouse studies with emphasis on Leishmania 
major infection relevant to vaccine development. In this 
regard in Venezuela, a clinical healing rate of more than 
95% was achieved, and cure was associated with a Th1-like 
immune response in the patients.16,17 A modified form of 
vaccine using pasteurized L. braziliensis promastigotes and 
live BCG was effective in the treatment of both refractory 
mucocutaneous Leishmaniasis and early cases of diffuse 
cutaneous Leishmaniasis.18
Based on the information from mouse models and 
human studies, the benign nature of the cutaneous dis-
ease, the ease with which L. major can be manipulated to 
yield the required material, and the ongoing practice 
of Leishmanization which allows rapid evaluation of 
candidate vaccine(s), little can be done to control the reser-
voirs or vectors. The observation that vaccinated individu-
als develop a Th1-mediated immune response, without 
being protected against infection, is in agreement with sev-
eral similar observations in mice and vervet monkeys,19,20 
and suggests that the induction of a Th1 immune response 
may be necessary, but not sufficient, for protection against 
cutaneous Leishmaniasis. However, a vaccine consisting of 
autoclaved L. major and BCG was used, shown to be safe 
and, significantly, it induced Interferon-gamma (IFN-γ) 
production in healthy volunteers.21 Care should be taken 
to avoid establishing settlements at the edge of, or within, 
involved forests. Insect repellents can provide limited pro-
tection for travelers.3,4 WHO have designated Leishmaniasis 
as a category 1 (emerging and uncontrolled) disease, with 
prevention focused on vector control, the control of ani-
mal reservoirs, and research into potential vaccines.6
In Brazilian studies, a killed promastigote vaccine 
derived from five Leishmania strains reduced the annual 
incidence of cutaneous Leishmaniasis in military recruits 
by 86%.3,4 When used as a recombinant protein expressed 
in Escherichia coli gp63 either failed to protect mice against 
L. major infection, or offered only partial protection in 
monkeys.22,23 In contrast, immunization with the native 
protein purified form L. major led to the protection of 
mice against challenge with either L. mexicana or L. 
major.24,25 These promising findings were overshadowed 
by variable (mostly negative) T cell responses in humans26–29 
and the inability of T cells from mice immunized with 
gp63 to elicit protective responses in macrophages.25 None-
theless, researchers have focused their efforts on gp63 
DNA-based vaccines (described below), and gp63-derived 
synthetic peptides. The latter were successfully tested in 
an animal model of cutaneous Leishmaniasis, and trig-
gered long-lasting T cells responses.30,31
To date, successful vaccination strategies against Leish-
maniasis have been limited to cutaneous Leishmaniasis, 
with small doses of living virulent L. major promastigote 
at a selected site.17 The clinical effectiveness of Leishma-
niasis immunization with the killed vaccine is not high 
at present.32 Phase III clinical trials in Ecuador and 
Colombia show that the Leishmania amazonensis vaccine is 
safe, but not effective.33,34
Spleen is the most important organ of the secondary 
lymphatic system and comprises white pulp (lymphocytes) 
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and red pulp (sinuses and blood vessels). The white pulp 
is where immune responses are induced, and antibodies 
are produced; important for secondary immune responses 
and adaptive immunity. The main concerns are reliable 
correlates of immunity that need to be developed to evalu-
ate vaccines, as well as a need for a uniform testing system 
for new vaccine candidates. Only later can the issues of de-
livery, antigen formulation and adjuvant be resolved. 
There is a pressing need to develop better animal models 
of visceral Leishmaniasis that can help the design of 
vaccines to control both canine and human disease in en-
demic areas. Currently, there seem to be as many problems 
and questions as there are solutions, but given the rapid 
progress in the field of vaccinology, a successful anti-
Leishmania vaccine should be achievable.
In this study, the results from each treatment group 
(1, 2, and 3) were evaluated statistically. The differences 
between the various injection doses used, the two types of 
mice used, and all three parameters (mouse type, injection 
dose, and injection group) were evaluated (Figures 1–3). 
Further studies are planned to investigate whether the mice 
in groups 1 and 3 produce IFN-γ or IL-4. We will also deter-
mine whether long term immunological memory is induced 
in the mice in groups 1 and 2. A limitation of this study is 
that we did not measure IFN-γ as a response indicator.
Comparison of the dose and injection groups shows 
that there were significant differences in SWP size (the 
minimum difference was seen at a dose 200 μg in group 1, 
the maximum at a dose 400 μg in group 2). Therefore, the 
optimal dose(s) to stimulate an immune response, IFN-γ 
production and long term immunological memory re-
quires further investigation.
The question to ponder here is whether BCG is of ben-
efit for the production of a delayed-type hypersensitivity 
response or not. Our results show that type I mice that are 
susceptible to cutaneous Leishmaniasis exhibited the 
greatest SWP expansion, but the effects of BCG on this 
expansion requires further study.
The vaccine dose, mouse type, and injection groups all 
affected each another. Each of the three factors had a 
notable affect on SWP size (minimum increase with a 
dose of 200 μg in group 1, and maximum increase with 
a dose of 400 μg in group 2, and 500 μg in group 3). 
Further evidence of a role for IL-10 comes from stud-
ies demonstrating increased IL-10 mRNA expression in 
bone marrow, lymph nodes and spleen.6 We hypothesize 
that the greatest increase in SWP expansion may be re-
lated to IL-4 and IL-10 production, resulting in humoral 
immune responses.6 Both IL-4 and IL-10 are associated 
with systemic disease without long term immunity to cu-
taneous Leishmaniasis, as suggested by our results in type 
I mice (susceptible) in injection group 3 at doses of 400–
500 μg. A cure was associated with a fall in IL-10 mRNA 
levels.6 SWP expansion is related to the production of cell 
mediated immune responses, IFN-γ and (most likely) IL-4 
suppression, that may lead to long term immunity to cuta-
neous Leishmaniasis, similar to our results in type II mice 
(resistant), in injection group 1 at doses of 100–200 μg.
The results of this study suggest that the optimal in-
jection dose(s) and injection protocol must be selected to 
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Figure 2. Sectional spleen pathology showed white pulp size 
expansion 38 days after Leishmania antigen intradermal injec-
tion plus a Bacillus Calmette-Guérin vaccine.
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Figure 3. Sectional spleen pathology showed white pulp size 
expansion 38 days after Leishmania antigen intradermal injec-
tion plus a Bacillus Calmette-Guérin vaccine plus booster dose 
after 14 days.
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stimulate cell-mediated immune responses, while inhibit-
ing the humeral immune system and preventing antibody 
production. These points must be addressed for progress 
to be made in the search for an effective vaccine against 
cutaneous Leishmaniasis.
In conclusion, the greatest increases in SWP size were 
seen at doses of 400–500 μg, with the greatest effect ob-
served in injection group 3. Injection group 1 showed a 
high response to the primary booster dose, which induced 
variable increases in SWP size, but BCG was not very effec-
tive. Therefore, the optimal injection dose, the type of ex-
perimental model, and the use of BCG as an adjuvant 
need to be determined in future studies.
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